Clinical efficacy of ranibizumab evidenced

Article

The ?real-world? clinical efficacy of ranibizumab has been demonstrated in a recently published study in the journal Clinical Ophthalmology.

The 'real-world' clinical efficacy of ranibizumab has been demonstrated in a recently published study in the journal Clinical Ophthalmology.

Led by Dr Jean-Marie Rakic (Centre Hospitalier Universitaire de Liège, Belgium), the team examined the treatment patterns of ranibizumab and the quality of life outcomes over a 2-year period in both real-world and clinical settings. A total of 267 patients suffering from wet age-related macular degeneration (AMD) were treated with 0.5 mg intravitreal injections of ranibizumab in this prospective, observational, multicentre, open-label study. Visual acuity, visual function, quality of life and safety were all assessed during follow up.

It was found that visual acuity improved to a statistically significant level from baseline by 2.5 months and these improvements were maintained to 6 months. However, this improvement was not statistically significant at 12 months and there was a decline from baseline by 24 months.

The majority of patients, however, were found to have improved or stable disease at the final time point and the visual function and quality of life scores were also improved and maintained at 24 months in just over a third of the study group.

Based on these results, the team summarized that the real-world clinical efficacy of ranibizumab was demonstrated. Additionally, the results highlighted the necessity of individualized treatment regimes to ensure optimal visual and quality of life outcomes.

For more detailed information please view the abstract here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.